Loading...
XNASBIIB
Market cap22bUSD
Dec 27, Last price  
151.31USD
1D
0.94%
1Q
-22.27%
Jan 2017
-46.64%
Name

Biogen Inc

Chart & Performance

D1W1MN
XNAS:BIIB chart
P/E
18.99
P/S
2.24
EPS
7.97
Div Yield, %
0.00%
Shrs. gr., 5y
-6.64%
Rev. gr., 5y
-6.07%
Revenues
9.84b
-3.32%
1,595,819,0001,713,619,0001,872,185,0003,171,617,0004,097,507,0004,377,348,0004,716,423,0005,048,634,0005,516,461,0006,932,199,0009,703,324,00010,763,800,00011,448,800,00012,273,900,00013,452,900,00014,377,900,00013,444,600,00010,981,700,00010,173,400,0009,835,600,000
Net income
1.16b
-61.89%
25,086,000160,711,000217,511,000638,172,000783,167,000970,132,0001,005,273,0001,234,428,0001,380,033,0001,862,341,0002,934,784,0003,547,000,0003,702,800,0002,539,100,0004,430,700,0005,888,500,0004,000,600,0001,556,100,0003,046,900,0001,161,100,000
CFO
1.55b
+11.77%
727,986,000889,503,000841,268,0001,020,635,0001,564,492,0001,074,898,0001,624,673,0001,727,741,0001,879,897,0002,345,078,0002,942,115,0003,716,100,0004,522,400,0004,551,000,0006,187,700,0007,078,600,0004,229,800,0003,639,900,0001,384,300,0001,547,200,000
Earnings
Feb 11, 2025

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
URL
https://www.biogen.com/
IPO date
Sep 17, 1991
Employees
8,725
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,835,600
-3.32%
10,173,400
-7.36%
10,981,700
-18.32%
Cost of revenue
7,497,700
6,913,000
7,285,200
Unusual Expense (Income)
NOPBT
2,337,900
3,260,400
3,696,500
NOPBT Margin
23.77%
32.05%
33.66%
Operating Taxes
135,300
632,800
52,500
Tax Rate
5.79%
19.41%
1.42%
NOPAT
2,202,600
2,627,600
3,644,000
Net income
1,161,100
-61.89%
3,046,900
95.80%
1,556,100
-61.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
(44,300)
(751,900)
(1,800,700)
BB yield
0.12%
1.86%
5.02%
Debt
Debt current
240,300
97,200
999,100
Long-term debt
7,588,200
6,947,000
6,934,800
Deferred revenue
Other long-term liabilities
781,100
944,200
1,320,500
Net debt
6,317,900
(83,500)
1,299,900
Cash flow
Cash from operating activities
1,547,200
1,384,300
3,639,900
CAPEX
277,000
(243,200)
(294,900)
Cash from investing activities
(4,101,000)
1,576,600
(563,700)
Cash from financing activities
149,300
(1,759,700)
(2,086,200)
FCF
1,025,400
1,749,000
3,560,100
Balance
Cash
1,049,900
4,892,800
3,802,500
Long term investments
460,700
2,234,900
2,831,500
Excess cash
1,018,820
6,619,030
6,084,915
Stockholders' equity
17,474,000
16,292,200
13,868,600
Invested Capital
21,990,180
14,164,870
13,624,085
ROIC
12.18%
18.91%
27.57%
ROCE
9.89%
15.44%
18.12%
EV
Common stock shares outstanding
145,600
146,000
149,600
Price
258.77
-6.55%
276.92
15.42%
239.92
-2.02%
Market cap
37,676,912
-6.81%
40,430,320
12.64%
35,892,032
-9.12%
EV
43,994,812
40,337,320
37,255,432
EBITDA
2,832,700
3,778,800
4,184,200
EV/EBITDA
15.53
10.67
8.90
Interest
246,900
246,600
253,600
Interest/NOPBT
10.56%
7.56%
6.86%